KYTX (Kyverna Therapeutics) ROE % Adjusted to Book Value : -86.36% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics ROE % Adjusted to Book Value?

Kyverna Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -52.68%. Kyverna Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 0.61. Kyverna Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -86.36%.

Kyverna Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Kyverna Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics ROE % Adjusted to Book Value Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

-309.16

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial						-	-31.32	-34.21	-61.96	-86.36

Competitive Comparison of Kyverna Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Kyverna Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyverna Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Kyverna Therapeutics's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Kyverna Therapeutics ROE % Adjusted to Book Value Calculation

Kyverna Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-188.59%	/	0.61
	=	-309.16%

Kyverna Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-52.68%	/	0.61
	=	-86.36%

Kyverna Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.